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SurvivalRapGEF1 (C3G) is a ubiquitously expressed protein that is essential for mammalian embryonic development.We
have shown earlier that C3G regulates cytoskeletal dynamics and is required for neuronal differentiation. To de-
termine if C3G plays a wider role in differentiation of multiple tissue types, we examined its role in skeletal mus-
cle differentiation using the model system of C2C12 cells in culture. C3G protein is highly expressed in mouse
skeletal muscle and its transcript and protein levels increase as C2C12 cells are induced to differentiate. Increase
in C3Gwas predominantly seen in the nuclei of myotubes. Ectopic expression of C3G promotedmyotube forma-
tion when cells were cultured in growth as well as differentiationmedium and, enhancedMHC levels were asso-
ciated with C3G expression. C3G induced differentiation required its catalytic and protein interaction domains
andwas dependent on the function of cellular R-Ras. Knockdownof cellular C3Gusing small hairpinRNA reduced
expression ofmuscle speciﬁcmarkers andβ-catenin, resulting in impaireddifferentiation. Disabling C3G function
also resulted in enhanced cell death suggesting that cellular C3G is required for cell survival. In cells grown in
growth medium, over-expressed C3G increased Akt activity, and C3G knockdown reduced it. C3G expression
also suppressed cyclin D1 levels, and induced p27 expression, molecules involved in regulating cell proliferation.
Endogenous C3G localizes to focal adhesions in myotubes and C3G expressing cells show distinct stress ﬁbers,
elongation and parallel alignment. Expression of a dominant negative construct of C3G, disrupts actin cytoskele-
ton and formation of focal adhesions resulting in detachment of cells from the substratum and inhibition of
differentiation. Our results provide evidence that C3G plays an important role in myogenic differentiation by co-
ordinating cell cycle exit, actin dynamics and survival signaling.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Early mammalian development involves coordinated regulation of
cell renewal and achievement of specialized functions through the pro-
cess of cell cycle arrest and differentiation. Development of the skeletal
muscle involves differentiation of myoblasts into myocytes which fuse
to formmultinucleated myotubes [1]. These steps are under the control
of myogenic transcription factors like MyoD and myogenin [2]. These
events are also recapitulated in adult skeletal muscle in response to
injury [3]. Myotube formation involves changes in cytoskeletal organi-
zation andmembrane fusion, in addition to altered gene expression [4].
Molecular determinants that signal to these events are not fully
understood.iation medium; GEF, guanine
BR, Crk binding region; ShRNA,
ily kinase; Cl-casp-3, cleaved
e 3-phosphate dehydrogenase.Guanine nucleotide exchange factors (GEFs) responsible for activa-
tion of small GTPases serve as important regulators of signaling path-
ways leading to diverse cellular functions. Through activation of
Rap sub-family of GTPases, RapGEF1 (C3G) is implicated in integrin
mediated signaling and cytoskeletal remodeling; thereby controlling
processes such as proliferation, differentiation, transformation and apo-
ptosis [5]. C3G is a 140 kDa, multi-domain protein with catalytic se-
quences at the C-terminal; and multiple proline rich sequences in the
central region (known as Crk binding region or CBR) through which it
interacts with SH3 domain containing molecules like Crk, Src family
kinases (SFKs) and c-Abl [6–8]. A region in theN-terminal is responsible
for interaction with E-cadherin [9]. The non-catalytic sequences are
known to negatively regulate exchange factor activity of C3G [10]. C3G
is activated by tyrosine phosphorylation at Y504, and through interac-
tion with Crk, and membrane association [11–13]. C3G has effector
functions dependent on both, or either its catalytic domain and protein
interaction domains. C3G is ubiquitously expressed and shows conser-
vation across vertebrate species as well as in Drosophila [5]. It is
expressed in fetal and adult mouse tissues and in several human cell
lines. Adult skeletal muscle and placenta show high expression levels
of C3G transcripts [14,15]. Mouse models lacking C3G show early
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allele have shown defects in vascular and nervous system development
[17]. Null mutants of C3G in Drosophila show partial lethality with de-
fects in muscle architecture [18].
C3G is an interacting partner of c-Abl and is required for actin cyto-
skeletal remodeling and ﬁlopodia formation [7]. In neuroblastoma cells,
C3G overexpression induces neurite growth and its knockdown com-
promises NGF induced differentiation [19]. C3G levels are upregulated
during differentiation of hematopoietic cells and neuronal cells, sug-
gesting that C3G plays an important role in differentiation of multi-
ple cell types. Our recent studies showed that C3G also interacts
with β-catenin and functions as a repressor of β-catenin dependent
transcription [20]. β-Catenin is a major effector of Wnt signaling
pathway and regulates cell proliferation and differentiation during
embryonic development and tissue morphogenesis [21].
We therefore aimed at investigating a role for C3G in skeletal muscle
differentiation using cell culture model of mouse mesenchymal C2C12
cells that can be induced to form multinucleate muscle ﬁbers positive
for myosin heavy chain (MHC) under conditions of growth in low
serum [22]. Molecular events in myogenic differentiation of C2C12
mouse mesenchymal cells are known to mimic events that take place
in vivo duringmuscle development. Increase in C3G RNA aswell as pro-
tein during C2C12 differentiation suggested that it may play a role in
myogenic differentiation. Thiswas examined by determining the conse-
quence of overexpressing or knocking down C3G. C3G overexpressing
cells showmyogenic differentiation reﬂected by enhancedmyotube for-
mation and expression of muscle speciﬁc protein, MHC. Disabling C3G
function compromisedmyogenic differentiation and caused cell detach-
ment and death. Activation of Akt and repression of cyclin D1 are some
of the molecular changes regulated by C3G in these cells.
2. Materials and methods
2.1. Cell culture, differentiation, transfections and treatments
Mouse myoblast cell line C2C12, was grown in Dulbecco's modiﬁed
Eagle'smedium (DMEM) containing 20% fetal calf serum.H9c2 ratmyo-
cardial cells were cultured in DMEM containing 10% fetal calf serum.
C2C12 cells at 90% conﬂuency were washed with DMEM and induced
to differentiate with differentiation medium (DM) containing 2% horse
serum in DMEM for 72–96 h. Differentiation medium was changed
every day during the period of differentiation. Mouse embryonic ﬁbro-
blasts (MEFs) derived from SV129XC57BLXCD1 mice were plated on
gelatin (0.01%) coated dishes and grown in differentiation medium for
24–144 h. H9c2 cells were differentiated by culturing sub-conﬂuent
cells in DMEM containing 1% fetal calf serum for 5 days. For transfecting
C2C12 cells, Lipofectamine-Plus reagent and Lipofectamine LTX from
Invitrogen were used as per manufacturer's instructions. Transfection
efﬁciency was generally in the range of 25–30%. PV treatment (inhibits
cellular tyrosine phosphatases and enables monitoring tyrosine phos-
phorylation on proteins), was given as previously described [23].
C2C12 cells were treated with 10 μM wortmannin (inhibitor of PI3K)
for 18 h prior to sample preparation. MAP kinase inhibitors, PD 98059
(20 μM), which inhibits ERK, or SB 203580 (10 μM), which inhibits
p38 were added to cells along with DM for 72 h.
2.2. Expression vectors and antibodies
Vectors expressingC3GandC3G-GFP, have been described previous-
ly [8,24]. pEGFP vectorwas fromClontech. Control vector pcDNA3.1was
obtained from Invitrogen Life Technologies. N and C terminal C3G dele-
tion constructs lacking N-terminal (ΔN) and C-terminal (ΔC) were gifts
fromDrM.Matsuda, Department of Pathology, Research Institute, Inter-
national Medical Centre of Japan, Tokyo. CBR expressing plasmid which
lacks both N andC terminalwas a gift fromDr P.J.S. Strok, OregonHealth
and ScienceUniversity. GFP-Rap1GAPwas provided by Dr Patrick Casey,Duke University School of Medicine. GFP-R-Ras43N dominant negative
construct was gifted by Dr Johan Peranen, Institute of Biotechnology,
and University of Helsinki, Finland. Adenoviral vectors were generated
using the AdEasy Systemprovided byDr Bert Vogelstein (JohnsHopkins
Kimmel Cancer Center, Baltimore,MDand JohnsHopkinsOncology Cen-
ter Baltimore, MD, USA). C3Gwas isolated from C3G-GFP N3 by BamH1,
followed by end ﬁlling with Klenow and Hind III digestion, and cloned
into the pShuttle-CMV plasmid digested with Hind III and EcoR V,
resulting in pShuttle-CMV-C3G. CBR was isolated from CBR-pcDNA3
by Hind III and Xba I digestion and cloned into the pShuttle-CMV plas-
mid digested with Hind III and Xba I under the control of the CMV pro-
moter terminated by SV40 polyadenylation signal, resulting in pShuttle-
CMV-CBR. Plasmid pAdTrack-CMV was used as control vector. AdEasier
cells were used to generate recombinant plasmids by homologous re-
combination. These recombinant adenoviral plasmids were used for
transfections in HEK 293T cells using Lipofectamine 2000 (Invitrogen).
After 18 days, cells were collected with media and subjected to three
freeze–thaw cycles, and the supernatant containing virus was used for
further rounds of infection to achieve high titer. Infection was done
with supernatant for 4 h in C2C12 cells and 60–80% cells showed ex-
pression by 48 h of infection.
pmU6, a U6 promoter-based vector was used to clone ShRNA direct-
ed against mouse C3G (ShA and ShC). Mouse C3G sequence targeted by
ShA was from nucleotides 3324 to 3342 and the sequence targeted by
ShC was from 331 to 349 (GenBankTM accession NM_001039087.1).
ShRNA having unrelated sequence of same length cloned in pmU6
was used as control (con-Sh). C3G, pY514C3G, β-catenin, α-tubulin,
myogenin, and CDK2 antibodies were from Santa Cruz (California,
USA). GAPDH, vinculin and actin antibodies were from Millipore (San
Diego, CA, USA). Cyclin D1, cleaved caspase 3, Akt and p-Akt (pS473)
antibodies were from Cell Signaling (Danvers, Massachusetts, USA).
Anti-MHC (A4-1025) mouse monoclonal antibody was derived using
a clone gifted by Prof. Blau H.M. (Department of Microbiology and Im-
munology, Stanford University School of Medicine, CA). C9 antibody,
which detects over-expressed C3G, was raised in our laboratory [7].
2.3. Indirect immunoﬂuorescence and western blotting
Cells were ﬁxed either with 4% formaldehyde or cold methanol and
immunostaining carried out as described earlier [8]. For visualization of
proteins, immunoﬂuorescence was performed using secondary anti-
bodies tagged with either Cy3 (Amersham) or Alexa 488 (Invitrogen).
Cells were stained for F-actin using Rhodamine phalloidin (Molecular
Probes). Non-speciﬁc signals due to secondary antibodies were ruled
out by carrying out incubations without adding primary antibodies.
This is indicated as blank in the ﬁgures. Images of stained cells were
captured using Leica TCS SP-5 AOBS confocal microscope from Leica
Microsystems (Germany), or Axioimager Z1 upright ﬂuorescence mi-
croscope from Carl Zeiss (GmBH, Jena, Germany). Western blotting
was done as described earlier [8]. Densitometric analysis of bands nor-
malized with corresponding loading controls was used to quantitate
the protein levels.
2.4. Quantitation of myotube formation, myotube length and apoptosis
Transfected cells were differentiated for the indicated time, ﬁxed
and stained with MHC antibody. Cells positive for MHC with three or
more nuclei were considered as myotubes. Percentage of myotubes
was calculated from ratio of expressing cells with three or more nuclei
to that of total number of transfected cells. Cell length was measured
using Carl Zeiss Axiovision Rel 4.7 software. Apoptotic cells were scored
by morphological observation as described earlier [8]. Expressing and
non-expressing cells that showed condensed chromatin, cell shrinkage,
membrane blebbing, and apoptotic body formationwere scored as apo-
ptotic. Data represent mean± s.d. of percent apoptotic cells after back-
ground (percent apoptosis in non-expressing cells) subtraction.
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RNA isolation was done using Trizol reagent (Sigma). Superscript
ﬁrst strand synthesis kit (Invitrogen) was used to make cDNA from
RNA. For Quantitative PCR, the RNA was treated with DNase I. PCR &
Q-PCR were performed using the cDNA for ampliﬁcation of C3G,
myogenin, MHC, GAPDH and actin using the same master mix of
template. Primers used for C3G were F-5′TCCTCCTTCCGAGCCTA3′, and
R-5′CCACCGCTTGGAGAAGTT3′; for myogenin were F-5′TGCCGTGGGC
ATGTAAGGT3′, and R-5′TGCGCAGGATCTCCACTTTAG 3′; for actin were
F-5′GGCTGTATTCCCCTCCATCG3′ and R-5′CCAGTTGGTAACAATGCCAT
GT 3′; for MHC were forward, 5′ CTTCAAGTTTGGACCCACGGT 3′ and
reverse 5′AGCCTCGATTCGCTCCTTTT 3′; and for GAPDH were F, 5′
TGAAGTCGCAGGAGACAACCT 3′ and R 5′ ATGGCCTTCCGTGTTCCTA 3′.
Densitometric analysis of bands normalized with corresponding load-
ing control was used to quantitate RNA levels.Fig. 1.C3G levels are upregulated during skeletalmuscle cell differentiation. (a) C3G protein leve
lysates were collected at 24 h intervals and subjected to western blotting for detection of C3G
3 independent experiments using tubulin as protein loading control is indicated in the bar d
growing cells, 3-day and 5-day differentiated H9c2 cell lysates were used for western blotting
during myogenic differentiation of MEFs. Lysates of MEFs differentiated for the indicated time w
tiation and GAPDH as protein loading control. (d) C3G transcript levels are upregulated upon C2
extracted fromundifferentiated (0 h), and differentiated C2C12 cell lysatesmade at 24 h interva
C2C12 cells (GM) and 96 h differentiated C2C12 cells (DM)were ﬁxed, costained with C3G and
with C3G and MHC primary antibodies. Images were captured using a ﬂuorescence microscop
(GM) and 96 h differentiated C2C12 cells (DM) were ﬁxed with methanol, and stained with C
captured using confocal microscope. Bar, 25 μm.2.6. Statistical analysis
Student's t test was used to determine the statistical signiﬁcance of
experiments.
3. Results
3.1. C3G expression increases during myocyte differentiation
A role for C3G in myogenic differentiation was investigated by ex-
amining C3G expression during the process of differentiation of C2C12
mouse myoblasts. Lysates of C2C12 cells grown in growth medium
(GM) or differentiation medium (DM) were prepared and subjected
to western blotting. C3G protein levels increased during differentiation
concomitant with an increase in myogenin, a muscle speciﬁc differenti-
ation marker (Fig. 1a). Results of several experiments show that C3Gls increase during C2C12 differentiation.Undifferentiated (0) anddifferentiated C2C12 cell
, myogenin and tubulin using indicated antibodies. Average change in levels of C3G from
iagram. *p b 0.05 (b) C3G levels increase during H9c2 cell differentiation. Exponentially
to detect C3G levels. CDK2 was used as protein loading control. (c) C3G protein increases
ere examined for C3G expression. MHC was used as a marker of skeletal muscle differen-
C12 differentiation. Semiquantitative PCRwas carried out using cDNA prepared from RNA
ls. (e) C3G expression and localization in C2C12myoblasts andmyotubes. Undifferentiated
MHC antibodies to detectmyotubes. Blank images represent cells that were not incubated
e. Bar, 20 μm. (f) C3G predominantly localizes to myotube nuclei. Exponentially growing
3G antibody. Blank images represent cells not incubated with C3G antibody. Images were
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was also observed upon differentiation of H9c2 rat cardiomyocyte cells
(Fig. 1b) and during myogenic differentiation of mouse embryonic ﬁ-
broblasts (Fig. 1c). The increase in C3G during differentiation was also
examined at the transcript level using semi-quantitative RT-PCR of sam-
ples prepared at different times during differentiation. C3G transcripts
increased coincident with increase in myogenin transcript levels
(Fig. 1d). C3G protein is also highly expressed in mouse skeletal muscle
tissues (Supplementary Fig. S1a). Treatment of cells with ERK and
p38MAPK inhibitors (PD98059 & SB203580 respectively) during differ-
entiation showed that the increase in C3G protein levels was dependent
on the activity of ERK, and not on p38MAPK (Supplementary Fig. S1b).
ERK is activated in a biphasic manner during C2C12 differentiation
[25], and may signal to C3G upregulation.
Increased levels of C3G protein were particularly observed in MHC
positive myotubes compared to myocytes which did not fuse (Fig. 1e).
Endogenous as well as exogenously expressed C3G was earlier shown
to predominantly localize to the cytoplasmic compartment [9,14,23,
26]. Since C3G levels increased during differentiation and appeared to
localize to the nucleus, we examined sub-cellular localization of C3G
protein in myocytes and myotubes by confocal microscopy. Single sec-
tion through the center of the nucleus showed very weak staining of
C3G in myocytes, but prominent staining in the nuclei of differentiated
myotubes (Fig. 1f). In addition to an increase in C3G protein level, we
also observed an increase in tyrosine phosphorylated C3G (pY514) as
cells were induced to differentiate (Supplementary Fig. S2). This was
detected under conditions of inhibition of tyrosine phosphatases by
pervanadate (PV) treatment, which enables detection of p-tyrosine
on proteins. Tyrosine phosphorylation is known to enhance catalytic
activity of C3G.Fig. 2. C3G over-expression promotes myotube formation. (a) C2C12 cells were transiently tra
captured to show myotube formation. (b) Quantitation of myotube formation (cells wit
72 h.*p b 0.05. (c) C3G over-expression increasesMHC expression. C3G or pcDNA3.1 plasmidsw
blotting using C3G,MHC and actin antibodies. Numbers indicate relative change inMHC level up
C2C12 cells were grown for 96 h, ﬁxed and stained for MHC. Images were captured using ﬂuor
pressing control virus or C3G virus for 48h.Numbers indicate change in transcript level compare
myogenic transcripts in C3G virus expressing cells compared to control. *p b 0.05.3.2. Overexpression of C3G enhances differentiation of C2C12 cells
The upregulation of C3G in various models of muscle differentiation
suggested that it may play an important role in myogenesis. We there-
fore examined the consequence of C3G overexpression in C2C12 cells
grown in GM or DM. Plasmids expressing GFP, or a fusion protein of
C3G with GFP were transfected into cells for 96 h and the morphology
of GFP positive cells examined. Compared to the ﬁbroblast-like mor-
phology seen in GFP expressing cells, C3G expressing cells were multi-
nucleate, spindle shaped and elongated when cultured in GM. As seen
in Fig. 2a, C3G overexpressing cells tended to fuse and form myotubes
even in GM.When grown in DM, C3G expression resulted in extensively
branched myotubes with multiple nuclei compared to that in GFP
expressing myotubes. A signiﬁcant increase was seen in number of
myotubes formed by C3G over-expression (Fig. 2b). C3G induced differ-
entiation was also examined by testing the expression of MHC under
conditions of C3G overexpression in C2C12 cells. Western blotting
(Fig. 2c) and indirect immunoﬂuorescence (Fig. 2d) showed enhanced
MHC levels in C3G expressing cells. The effect of C3G expression on
myogenic transcripts, myogenin & MHC in cells cultured in GM was
examined by real-time PCR and semi quantitative RT-PCR. At 48 h of
C3G infection, levels of both transcripts showed a signiﬁcant increase
(Fig. 2e & f).
We have earlier shown that C3G can initiate signaling independent
of its catalytic activity. To examine if the ability of over-expressed C3G
to induce differentiation was dependent on its catalytic domain, dele-
tion constructs having only the catalytic domain (ΔN-C3G) or not
having the catalytic domain (ΔC-C3G) were examined for their ability
to induce myocyte fusion (Fig. 3a). The ΔN-C3G construct is known to
show constitutive catalytic activity towards Rap [13] and ΔC-C3G isnsfected with either C3G-GFP or GFP, and grown in GM or DM for 96 h, ﬁxed and images
h 3 or more nuclei) in GFP and C3G-GFP expressing cells cultured in GM or DM for
ere used to transiently transfect C2C12 cells for 48 h and lysateswere subjected towestern
on C3G expression using actin as internal control. (d) Control and C3G adenovirus infected
escence microscope. Bar, 20 μm. (e) Myogenin & MHC transcript levels in C2C12 cells ex-
d to control, normalizedwithGAPDH. (f) Real time PCR basedquantitation of expression of
Fig. 3.Catalytic domain of C3G is required formyotube formation. (a) Schematic diagram and expression levels of C3G and its deletion constructs. (b) C2C12 cells transfectedwith C3G and
its deletion constructs, or GFP as control, were cultured for 96 h, ﬁxed and stained for C3G. Images were captured to showmorphology of expressing cells. Bar, 50 μm. (c) Quantitation of
myotube formation induced by over-expressed C3G and its deletion constructs. Bar diagram shows percentage of expressing C2C12 cells forming myotubes depicted asmean± s.d. from
three independent experiments. *p b 0.001. (d) Quantitation of length of cells expressing C3G and its deletion constructs. Bar diagram shows average cell length asmean± s.d. from three
independent experiments. *p b 0.001. (e) Involvement of GTPase effectors of C3G, R-Ras & Rap1 inmyogenic differentiation. Cells grown in growthmedium for 96 h after cotransfection of
C3G with either control, GFP-Dn R-Ras (inhibits R-ras signaling), pcDNA, GFP-Rap1GAP (inhibits Rap1 signaling) plasmids were ﬁxed, and stained for C3G. Bar, 50 μm. (f) Length of
coexpressing cells in captured images was measured using Carl Zeiss Axiovision Rel 4.7 software. Bar diagram shows average length of expressing cells as mean ± s.d. *p b 0.0001.
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C3G [27]. It was observed that both the deletion constructs were com-
promised in their ability to enhance differentiation and cells expressing
ΔN and ΔC showed signiﬁcantly lower myocyte fusion (Fig. 3b, c) as
well as reduction in myocyte length (Fig. 3d). In fact, several ΔC ex-
pressing cells showed rounded morphology, indicative of apoptosis.
These results indicate that both the catalytic domain and protein inter-
action domain are required for C3G to trigger signaling leading
to myocyte fusion. The requirement of catalytic activity of C3G forinduction of differentiation supports the observation of enhanced levels
of phosphorylated C3G in differentiated cells.
The catalytic activity of C3Gappears to be essential, as deletion of the
catalytic domain totally blocked its ability to induce differentiation. We
therefore examined the involvement of two known GTPase targets of
C3G; R-Ras and Rap1 by co-expression of dominant negative constructs
(R-Ras43N&Rap1GAP),which function to inhibit signalingmediated by
cellular R-Ras & Rap1 respectively. We observed that coexpression of
GFP-R-Ras43N with C3G signiﬁcantly inhibited myotube formation
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myotube formation.
3.3. C3G is required for myocyte differentiation
Since C3G levels increased during C2C12 differentiation, we directly
tested its requirement for myogenic differentiation using small hairpin
RNA (ShRNA) mediated knockdown of cellular C3G. C2C12 cells were
transfected with control ShRNA (con-Sh) and ShRNA that targets C3G
(ShA) and whole cell lysates subjected to western blotting to detect
levels of C3G and myogenin. Cells expressing ShA showed more
than 50% reduction in C3G levels and also a reduction in myogenin
levels compared to control ShRNA expressing cells (Fig. 4a). Similarly,
reduction in MHC was observed by using an alternate ShRNA (ShC)
(Fig. 5b). Examination of myotube formation under differentiation con-
ditions by staining for MHC showed that ShC expressing cells did not
align and fuse to form myotubes efﬁciently. In fact, detachment from
the substratum and extensive cell death was seen in these cells. ThisFig. 4. C3G is required for myotube formation. (a) Knock down of C3G using ShRNA affects myo
and lysates subjected towestern blotting with indicated antibodies. Numbers indicate relative c
knock down decreases myotube formation. con-Sh or ShC constructs were over-expressed in C
and images captured. Bar, 50 μm. (c) C3G knock down disrupts actin organization. ShC or con-S
with Rhodamine-phalloidin. Imageswere captured using confocalmicroscope. Bar, 10 μm. (d) C
either ShC or con-Sh constructs alongwith GFP, and ﬁxed cells stained for cleaved caspase 3. Im
in cells expressing con-Sh or ShC alongwith 20 ng of GFP and grown for 48 h in either GM or DM
apoptosis in non-expressing cells in the same coverslips. *p b 0.05.was conﬁrmed by examining the actin cytoskeleton and cell death in
control and ShC expressing cells, co-transfected with GFP for 48 h.
Rhodamine-phalloidin staining showed distinct F-actin ﬁlaments and
well adhered cells when transfected with control ShRNA, whereas a
large number of ShC expressing cells showed loss of actin stress ﬁbers
and rounding off (Fig. 4c). Activation of apoptosis in these cells was ex-
amined by staining for the presence of cleaved caspase-3 (Cl.-casp3), an
indicator of caspase-3 activation and a marker of apoptosis. A majority
of ShC expressing cells that showed detachment from the substratum
were positive for Cl-casp3 (Fig. 4d). Quantitation of apoptosis seen in
cells expressing ShC under conditions of growth in either GM or DM is
shown in Fig. 4e. These results indicate that cellular C3G functions to
aid myocyte fusion and also enables cell survival.
3.4. C3G regulates Akt activity in C2C12 cells
It is known that apoptosis occurs as myocytes are induced to differ-
entiate to form myotubes under conditions of serum starvation [28].genin levels. C2C12 cells were transiently transfectedwith either con-Sh or ShA constructs
hange inmyogenin levels upon knockdown of C3G using actin as internal control. (b) C3G
2C12 cells for 24 h, followed by differentiation for 72 h, ﬁxed, stained with MHC antibody
h constructs were cotransfectedwith GFP in C2C12 cells, grown for 48 h, stained for F-actin
3G knockdown causes cell death. C2C12 cells were grown for 48h after cotransfectionwith
ageswere taken using a ﬂuorescencemicroscope. Bar, 20 μm. (e) Quantitation of apoptosis
. Data represents average of % apoptotic cells among GFP positive cells after subtraction of
Fig. 5.C3G over-expression activates Akt and decreases cyclinD1 levels. (a) C3G activates Akt. Control, C3G and CBR adenovirus infected C2C12 cells were grown for 72 h. Cell lysateswere
subjected to western blotting using pAkt, Akt, and C3G antibodies. Numbers indicate relative pAkt levels (adjusted with total Akt). Bar diagram shows relative pAkt levels as mean ± s.d.
from three independent experiments. (b) Knock down of C3G decreases pAkt levels. C2C12 cells were transfected with con-Sh and ShC constructs for 48 h and cell lysates subjected to
western blotting to detect pAkt, Akt, MHC, C3G and actin using indicated antibodies. Numbers indicate relative change of the respective proteins compared to that seen in controls.
(c) β-catenin levels increase during differentiation. Western blot shows β-catenin, MHC and C3G levels in undifferentiated & 72 h differentiated C2C12 cells. Numbers indicate relative
β-catenin levels adjusted with actin. (d) Effect of C3G knockdown on cellular β-catenin levels. C2C12 cells were transfected with con-Sh and ShC constructs, for 36 h and cell lysates
subjected to western blotting to detect C3G, actin and β-catenin. Relative β-catenin levels from three independent experiments represented asmean± s.d. are shown in the bar diagram.
(e) C3G expression represses cellular cyclin D1 expression.Western blot of lysates from control and C3G adenoviral construct expressing cells (72 h) probed for C3G, cyclin D1 & GAPDH.
Bar diagram shows relative cyclin D1 levels averaged from 3 experiments. (f) Induction of p27 in C3G over-expressing cells. Lysates of cells expressing control and C3G adenoviral con-
structs were subjected to western blotting to detect C3G, p27 and actin.
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cell survival signaling. Since Akt activation is a major regulator of cell
survival, we examined whether C3G overexpression induces phosphor-
ylation of Akt, an indication of its activation. C2C12 cells were infected
with control virus and C3G or CBR overexpressing virus for 72 h and
subjected to western blotting to detect p-Akt and Akt. A signiﬁcant in-
crease in pAkt levels was seen in lysates from cells expressing C3G
(Fig. 5a). Cells expressing the deletion construct, CBR showed a small in-
crease in levels of pAkt (compared to C3G). The increase in pAkt levels
in response to C3G expression was not particularly dependent on activ-
ity of PI3K, as increased pAkt levels were also seen under conditions of
wortmannin treatment (Supplementary Fig. S3). pAkt levels increase
concomitantly with an increase in C3G levels during C2C12 differentia-
tion (Supplementary Fig. S4a).We therefore examined the consequence
of reducing cellular C3G levels on pAkt activation in C2C12 levels.
Cells expressing ShRNA targeting C3G show reduced pAkt levels com-
pared to cells expressing control ShRNA (Fig. 5b and Supplementary
Fig. S4b). These results suggest that C3G plays a role in myocyte differ-
entiation by regulating activity of Akt.
We have earlier shown that C3G functions as a repressor of β-
catenin activity. Since it is known that β-catenin plays an important
role in regulating myocyte proliferation vs. differentiation, we exam-
ined β-catenin levels in C2C12 cells under conditions of C3G knock-
down. Results from others, as well as our own study showed that
β-catenin protein levels increase upon myogenic differentiation of
C2C12 cells [29] (Fig. 5c & Supplementary Fig. S4a). Reduction of cel-
lular C3G results in signiﬁcantly lower levels of β-catenin (Fig. 5d)
suggesting that regulation of β-catenin function may be one of the
mechanisms engaged by C3G to induce differentiation. C3G express-
ing cells also showed a decrease in cyclin D1 levels (Fig. 5e). These
results are in agreement with previous ﬁndings which have shown
that repression and degradation of cyclin D1 are associated withmyogenic differentiation [30,31]. Induction of cell cycle inhibitors,
p21 and p27 is a hall mark of cell cycle withdrawal during myocyte
differentiation [32]. In addition to repression of cyclin D1, we ob-
served that C3G overexpression results in an increase in p27 levels
(Fig. 5f).3.5. C3G is required for formation of intact focal adhesions
Expression of the central Crk binding region (CBR) of C3G that lacks
both N and C-terminal sequences functions as a dominant negative to
inhibit endogenous C3G activation [33]. C3G and CBR were expressed
in C2C12 cells using adenoviral expression vectors and cultured for
96 h. CBR expressing cells failed to fuse and formmyotubes. They showed
detachment from the substratum, and change in cell morphology
(Fig. 6a) indicating that endogenous C3G function was required for sur-
vival and fusion of myocytes. Examination of F-actin in these cells
grown for 48 h in growth medium showed loss of F-actin ﬁlaments and
disruption of intact actin cytoskeleton in CBR expressing cells (Fig. 6b).
It was observed that C3G expressing cells show elongation and better
alignment with prominent stress ﬁbers compared to control virus ex-
pressing cells indicating that C3G expression enables actin cytoskeletal
remodeling that favors myoblast elongation and fusion.
Several proteins that play a role in regulating actin remodeling
and cell adhesion have been shown to aid myoblast fusion [34]. Earlier
studies have implicated a role for C3G in cell adhesion through its local-
ization to focal adhesions (FAs) [35,36]. We therefore examined the
presence of C3G at FAs in myocytes and myotubes by examining
colocalization with vinculin. It was observed that endogenous C3G was
not seen at FA sites in myoblasts but showed partial colocalization with
vinculin inmyotubes (Fig. 6c). This dynamic localization of C3G suggests
its contribution to cell fusion during the formation of myotubes.
Fig. 6. C3G is required for cell adhesion and survival. (a) CBR over-expression causes cell death and inhibits myotube formation. C2C12 cells infectedwith control, C3G and CBR adenoviral
constructs were grown for 96 h and live cell imaging carried out. Bar, 100 μm. (b) CBR over-expression causes disruption of F-actin ﬁlaments. C2C12 cells were infected with control, C3G
and CBR adenoviral constructs, grown for 48h,ﬁxed and stained to detect F-actinwith Rhodamine phalloidin. Bar, 50 μm. (c) C3G localizes at focal adhesions inmyotubes. Undifferentiated
myocytes and 96 h differentiated C2C12 cells (myotubes) were subjected to immunoﬂuorescence with C3G and vinculin antibodies. Images were taken using confocal microscope. Bar,
10 μm. (d) CBR overexpression causes loss of focal adhesions. C2C12 cells cotransfected with paxillin-GFP and C3G or CBR, were grown for 48 h, ﬁxed and followed by staining with
C3G antibody. Imageswere captured using confocalmicroscope. Bar 10 μm. (e) CBR over-expression causes cell death. C2C12 cellswere infectedwith CBR, or control adenoviral constructs
and grown for 48 h before cell lysates were collected to performwestern blotting using cleaved caspase 3, C3G and actin antibodies. C2C12 cell lysate collected after 24 h treatment with
20 μg/ml cycloheximide and 30 ng/ml TNFαwas used as positive control. (f) Quantitation of apoptosis in cells expressing control and CBR adenovirus for 48 h.
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entiation [37]. We examined if detachment and rounding of CBR ex-
pressing cells were due to loss of focal adhesions. C3G and CBR were
coexpressed with GFP-paxillin, and FAs in expressing cells examined by
GFP signals. FAs are prominently seen in non-expressing cells as well as
C3G expressing cells; but CBR expressing cells showed absence of FAs
(Fig. 6d), indicating that CBRdisrupts formationof FAswhich are required
for cell adhesion and differentiation. CBR expressing cells also showed
condensed chromatin (Supplementary Fig. S5) and higher level of Cl-
casp-3 compared to uninfected or control virus infected cells (Fig. 6e) in-
dicating that disabling the function of endogenous C3G results in activa-
tion of apoptotic pathways. Quantitation showed a signiﬁcant increase
in cell death in CBR expressing cells compared to control cells (Fig. 6f).
4. Discussion
Our results provide evidence for the role of a GEF, C3G as a determi-
nant of skeletal muscle cell differentiation. The increase in levels of C3Gexpression seen during differentiation of skeletal muscle cells and our
results showing that knockdown of C3G compromises muscle cell dif-
ferentiation are indicative of the requirement of C3G for muscle devel-
opment. Additionally, expression of a dominant negative construct
that blocks C3G activity, interferes with the differentiation process.
The catalytic as well as protein interaction domain of C3G are required,
as expression of the independent domains did not promote differentia-
tion. An increase in the catalytically active component of C3G during dif-
ferentiation and dependence on the activity of R-Ras GTPase, further
validate the requirement of catalytic activity for the differentiation pro-
cess. Our data shows that C3G expression in cells cultured in normal
growth medium results in induction of myogenic markers and fusion
of cells to formmyotubes. C3G is therefore capable of initiating signaling
events that result in myogenic gene expression and actin cytoskeletal
changes required for cell fusion even in the absence of conditions that
favor differentiation to a muscle lineage. Under conditions of C3G ex-
pression in cells grown in differentiationmedium,we observe increased
number and extensive branching of myoﬁbers, indicative of increased
2637K. Sasi Kumar et al. / Biochimica et Biophysica Acta 1853 (2015) 2629–2639myotube–myotube fusion suggesting that high levels of C3G expression
enhance the fusion process.
During differentiation, C3G levels increase up to 48 h after which,
levels appear to plateau. Similar kinetics of expression was also ob-
served for myogenin. Increase was also seen at the transcript level indi-
cating that C3G is under transcriptional regulation during induction of
differentiation. In silico analysis of upstream sequences of C3G gene,
showed the presence of binding sites formyogenic transcription factors,
which require experimental validation. C3G expression also results in
changes in gene expression of myogenic regulatory factors, suggesting
that C3G can signal to enhance levels of these transcripts. This may be
one of the mechanisms by which over-expressed C3G can initiate
myogenesis even in the absence of differentiation inducing signals.
The high level of C3G protein seen in myotubes was particularly lo-
calized to the nuclei suggesting that C3G contributes to the differentia-
tion process by altering speciﬁc nuclear functions. Though C3G protein
shows the presence of putative nuclear localization signals, this is the
ﬁrst documentation for its presence in the nuclear compartment. Al-
tered chromatin dynamics and changes in gene expression are essential
features of myogenesis [38]. Some cytoskeletal regulatory factors like
Kindlin2 and smALP undergo nuclear translocation during C2C12 differ-
entiation [39,40]. As a known interacting partner of β-catenin, which
has essential nuclear functions in skeletal myogenesis, C3G may also
serve a regulatory role by translocating to the nucleus. This remains to
be investigated. In addition to an increase in C3G protein levels during
differentiation,we also observed an increase in tyrosinephosphorylated
C3Gwhich is catalytically active. SFKs and c-Abl interact with and phos-
phorylate human C3G at Y504 [7,23]. c-Abl and c-Src activity is known
to increase upon differentiation of C2C12 cells [41,42] and may be re-
sponsible for an increase in catalytically active C3G.Fig. 7. Schematic ﬁgure showing the role of C3G in skeletalmuscle differentiation of C2C12myo
(transcript and protein) as cells fuse to formmyotubes. (b) Overexpression of C3G in C2C12 ce
actin organisation, resulting in cell fusion to formmyotubes. On the other hand, reducing C3G fu
differentiation medium. Compromised C3G function results in disruption of focal adhesions leaFailure of myoblasts expressing ShRNA targeted to knockdown
endogenous C3G to fuse and form multi-nucleated myotubes indi-
cated that optimal level of endogenous C3G is required for myocytes
to undergo differentiation. Knockdown of C3G also resulted in lower
levels of muscle speciﬁc genes suggesting that C3G may be an up-
stream regulator of myogenic molecules, and therefore activates
the differentiation program. Induction of differentiation in myocytes
is associated with cell death and activation of cell survival pathways
has been a downstream effect of molecules that induce differentia-
tion. Our over-expression and knockdown experiments have shown
that C3G signals to activation of Akt. Activation of Akt is required for
expression of myogenic factors and cell cycle withdrawal promotes
induction of Akt [43]. C2C12 cells do not differentiate when cultured
in the presence of Akt inhibitor [44]. Unpublished results from our
lab have shown that C3G expression results in Akt activation in
human breast cancer cells. Expression of CBRin C2C12 cells also results
in a small increase in pAkt levels at 72 h of expression, though these
cells do not differentiate. These observations indicate that change in
Akt activity is due to expression of C3G, and not a consequence of myo-
genic differentiation.
Reduction in C3G levels resulted in loss of cells due to cell death, in-
dicated by activation of caspase-3. It therefore appears that C3G acti-
vates survival signaling in parallel with activation of the myogenic
program. In addition to regulating expression of MHC, C3G was shown
to inhibit cyclin D1 and increase levels of the cell cycle inhibitor, p27.
Repression of cyclin D1 expression and induction of p27 are associated
with cell cycle withdrawal and differentiation [31,45–47]. The effect of
C3G on cyclin D1 & p27 levels could be at the transcriptional or post-
transcriptional level. This remains to be investigated. The fact that C3G
alters Akt activity and expression of myogenic and cell cycle regulatorsblasts. (a) C2C12 cells cultured in differentiationmedium for 72–96 h show increase in C3G
lls cultured in GM results in an increase in Akt activity and myogenic markers; and altered
nction inhibits Akt activity, MHC levels, andmyotube formationwhen cells are cultured in
ding to detachment and death of myocytes.
2638 K. Sasi Kumar et al. / Biochimica et Biophysica Acta 1853 (2015) 2629–2639in cells cultured inGM, indicates that changes in thesemolecules are not
due to secondary effects of differentiation.
β-Catenin is required for myogenic differentiation of skeletal mus-
cle as well as C2C12 cells [48,49]. It interacts directly with MyoD to en-
hance its activity [50]. Our results show that cellular C3G is required
for maintaining optimum levels of β-catenin. In epithelial cells C3G
represses β-catenin levels by altering its stability and inhibits its
activity [20]. Therefore, C3G shows cell type dependent regulation of
β-catenin function, and the mechanisms involved need to be investi-
gated. Cell-type dependent regulation of β-catenin is not unusual and
has been shown earlier [51].
Of the known targets, C3G engages R-Ras and not Rap GTPase in in-
ducing differentiation. This ﬁnding also substantiates an earlier study
showing that R-Ras is a positive regulator of skeletal myogenesis [52].
Several small GTPases and their regulatory GEFs and GAPs are involved
in myoblast fusion; which is an essential step during muscle develop-
ment [53]. It is known that cell membrane protrusions propelled by
actin, enable cell–cell fusion [54]. The role of C3G in dynamic reorgani-
zation of actin to promoteﬁlopodia and neurite like extensions has been
shown earlier [7,24]. C3G expression resulted in formation of organized
F-actin ﬁbers that enables change in shape to spindle-like cells. Since
fusion is known to occur only between elongated spindle shaped
myocytes, the morphological changes caused by C3G may be contrib-
uting to cell fusion. Studies on Drosophila wherein the C3G orthologue
has been knocked out, show abnormalities in muscle morphology
during larval development [18]. The defects are caused by improper
attachment of long muscles due to alteration in integrin localization.
Enhanced C3G expression was also seen in the rat myocardium in
peri-infarct regions and the authors have suggested a role for C3G in
post-infarction cardiac muscle remodeling [55].
During myoblast differentiation, vinculin and paxillin are recruited
from the cytoplasmic pool into FAs [56]. Our study also shows that
C3G localizes to focal adhesions in myotubes and expression of domi-
nant negative C3G results in improper formation of FAs and detachment
of cells from the substratum. Similar detachment of cells was also
observed upon knockdown of endogenous C3Gusing ShRNA. C3G inter-
acts with E-cadherin, a molecule that plays an important role in muscle
cell membrane fusion [9]. The localization of C3G to FA sites and loss of
adhesion seen in cells expressing dominant negative C3G suggests
its role in maintaining attachment sites that are required for muscle
cell fusion.
We have earlier shown an increase in C3G levels during differentia-
tion of neurons and hematopoietic cells and its requirement for neural
differentiation [5,19]. Results of the present study demonstrating re-
quirement of C3G for muscle differentiation raise the possibility of
C3G being an important regulator of differentiation of a variety of tissue
types during embryonic development. Muscle speciﬁc gene transcripts
are seen at 8–9 d of development in themouse embryo [57]. C3G knock-
out mice die around embryonic d7.5; at which time tissue speciﬁc dif-
ferentiation of various cells is observed. One of the reasons for early
embryonic lethality seen in knockoutmice could therefore be due to de-
fective differentiation of various tissues. Our results provide insights
into the role of C3G in skeletal muscle differentiation which occurs by
regulation of molecules involved in myogenic program, cell prolifera-
tion arrest, adhesion and survival signaling (Fig. 7).
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